Abstract: Fusion proteins that contain the fusion of (i) a peptide of less than 100 amino acids comprising a first amino acid sequence comprising AASSG (SEQ ID NO: 1) and a second amino acid sequence comprising XAGXDXXTEXPXS (SEQ ID NO: 2), wherein X designates any amino acid, and (ii) a protein transduction domain (PTD) are provided, along with pharmaceutical compositions containing the fusion protein. The proteins can be used to treat Huntington's disease.

Abstract: Novel therapeutic compounds for use against Huntington's disease. More especially, an isolated peptide of size less than 100 amino acids and containing: a first sequence having at least 80% identity with sequence AASSG (SEQ ID NO: 1), or a second sequence having at least 80% identity with sequence XAGXDXXTEXPXS (SEQ ID NO: 2), where X designates any amino acid. The use of an isolated peptide of size less than 200 amino acids and containing the sequence(s) defined above, as a drug is also described.

Abstract: This invention is based on the identification of the role played by the receptor mX on certain insects through the behavior evinced in the taste sensory reactions of these insects. The invention addresses the use of the modulators on the mX receptor, such as L-canavanine and/or a mix of arginine and calcium and/or N-methyl-L-arginine (NMA) which are used to prepare a compound with repellent or attractive qualities with regard to certain insects. The invention also concerns the use of an mX insect receptor as a target for the identification of repellent substances regarding at least some insects.